


Under the Paperwork Reduction Act



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

<i>Complete if Known</i>	
Application Number	10/661,947
Filing Date	09/12/2003
First Named Inventor	Charles Eric Mowbray
Art Unit	1626
Examiner Name	Not yet assigned
Attorney Docket Number	PC25375A

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>8</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
<i>MB</i>	AB	WO 91/11172	08-08-1991	The University of Kansas		
<i>MB</i>	AC	WO 94/02518	02-03-1994	The University of Kansas		
<i>MB</i>	AD	WO 98/55148	12-10-1998	Janssen Pharmaceutica N.V.		
	AE	WO 02/04424	01-17-2002	Pfizer Limited		
<i>MB</i>	AF	WO 02/04424 (Corrected Version)	01-17-2002	Pfizer Limited	pp. 4-18, for example Claims 1 and 14 and 33	
<i>MB</i>	AG	WO 02/085860	10-31-2002	Pfizer Limited	151, 152, for example	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). <sup>2</sup>See Kinda Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Indicate document by the appropriate symbols as indicated on the document under WIPO Standard ST.15 if possible. <sup>6</sup>Applicants is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

## Information Disclosure Statement

Page 1 of 2

**BEST AVAILABLE COPY**

Substitute for Form 1449/PTO

**Complete if Known**

Application Number	10/661,947
Filing Date	09/12/2003
First Named Inventor	Charles Eric Mowbray
Art Unit	1626
Examiner Name	Not yet assigned
Attorney Docket Number	PC25375A

**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MB	AH	BERGE, et al., "Pharmaceutical Salts," <i>Journal of Pharmaceutical Sciences</i> , 1977, pp. 2-19, Vol. 66, No. 1.	
MB	AI	BIGHLEY, et al., "Salt Forms Of Drugs And Absorption," <i>Encyclopedia Of Pharmaceutical Technology</i> , 1996, pp. 453-497, Vol. 13.	
MB	AJ	FERRES, H., "Pro-Drugs Of $\beta$ -Lactam Antibiotics," <i>Drugs of Today</i> , 1983, pp. 499-538, Vol. 19, No. 9.	
<i>No Relevance PP Pursue</i>		BUDDGAARD, H. et al., <i>Design of Prodrugs</i> , 1985, Elsevier Press.	
MB	AK	GENIN, M. et al., "Novel 1,5-Diphenylpyrazole Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors with Enhanced Activity Versus The Delavirdine-Resistant P236L Mutant: Lead Identification and SAR of 3- and 4-Substituted Derivatives," <i>J. Med. Chem.</i> , 2000, page 1034-1040, Vol. 43.	

EXAMINER:	DATE CONSIDERED:
	4/22/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.